Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cns Pharmaceuticals Inc
(NQ:
CNSP
)
0.1660
-0.0040 (-2.35%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cns Pharmaceuticals Inc
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reaches Planned Enrollment Berubicin Study for the Treatment of GBM
January 18, 2024
Via
Investor Brand Network
Exposures
Product Safety
Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directors
January 18, 2024
Via
ACCESSWIRE
CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
January 17, 2024
Via
ACCESSWIRE
12 Health Care Stocks Moving In Tuesday's After-Market Session
January 16, 2024
Via
Benzinga
CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin
December 18, 2023
Via
ACCESSWIRE
CNS Pharmaceuticals to Participate at the Virtual Investor Ask the CEO Conference
October 19, 2023
Via
ACCESSWIRE
Multidisciplinary Consortium Sets Sights on Developing AI to Detect Gliomas
January 10, 2024
Via
Investor Brand Network
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Light, Viruses Could Transform Brain-Tumor Treatment
December 28, 2023
Via
Investor Brand Network
12 Health Care Stocks Moving In Monday's After-Market Session
December 18, 2023
Via
Benzinga
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces DSMB Recommendation to Continue Pivotal GBM Study without Modification
December 18, 2023
Via
Investor Brand Network
Researchers Discuss How Brain Cancer Radiotherapy Side Effects Can Be Reduced
December 15, 2023
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Interim Analysis on Global Berubicin Trial Showing Promising Results
December 06, 2023
Via
Investor Brand Network
Topics
Death
Exposures
Death
How CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No Cure
December 06, 2023
Via
ACCESSWIRE
How CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No Cure
December 05, 2023
Every form of cancer is devastating, but the unfortunate reality is not all cancers are created equal. There are certain forms that are more deadly, with Glioblastoma (GBM) being one of the worst. GBM...
Via
Benzinga
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Presents Updated Safety Data from Berubicin Study at SNO Annual Gathering
November 22, 2023
Via
Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy
November 22, 2023
Via
ACCESSWIRE
Study Finds DNA Loops in Brain Tumors in Kids Amplify Relapse Risk
November 21, 2023
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Release Interim Data by Year End for Lead Treatment Candidate Berubicin
November 16, 2023
Via
Investor Brand Network
Topics
Death
Exposures
Death
CNS Pharmaceuticals To Release Interim Data By The End Of The Year For Potential Glioblastoma Drug Candidate
November 16, 2023
Via
ACCESSWIRE
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Q3 2023 Financial Results, Update on Berubicin Study
November 15, 2023
Via
Investor Brand Network
CNS Pharmaceuticals To Release Interim Data By The End Of The Year For Potential Glioblastoma Drug Candidate
November 15, 2023
Glioblastoma is a highly aggressive type of brain cancer with no cure, leading to a grim prognosis and average survival time of only 14 to 16 months. With no approved treatment for recurrent GBM...
Via
Benzinga
CNS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study Before Year End
November 15, 2023
Via
ACCESSWIRE
Brain Cancer Reemergence Could Soon Be Detected Using a Finger-Prick Test
November 09, 2023
Via
Investor Brand Network
Stanford Study Finds Lung Cancer Cells Hide, Thrive in the Brain
October 27, 2023
Via
Investor Brand Network
Spanish Clinical Trial to Explore Marijuana as Glioblastoma Treatment
October 24, 2023
Via
Investor Brand Network
Topics
Cannabis
Exposures
Cannabis
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Advancing Drive Toward Potential New GBM Treatment
October 20, 2023
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Announces Participation at Upcoming Virtual Investor Ask the CEO Conference
October 19, 2023
Via
Investor Brand Network
Sonobiopsy Promises Easier Way to Diagnose Brain Tumors
October 18, 2023
Via
Investor Brand Network
Why Streamline Health Solutions Shares Are Trading Lower By Over 68%? Here Are Other Stocks Moving In Monday's Mid-Day Session
October 16, 2023
Gainers MingZhu Logistics Holdings Limited (NASDAQ: YGMZ) shares gained 64% to $0.7798 after gaining more than 10% on Friday.
Via
Benzinga
BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Innovative Glioblastoma Treatment ‘Could Offer Hope’
October 16, 2023
Via
Investor Brand Network
Exposures
Product Safety
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.